2025 Q3 -tulosraportti
48 päivää sitten36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
925
Myynti
Määrä
300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 300 | AVA | NON | ||
| 57 | NON | AVA | ||
| 20 | NON | NON | ||
| 500 | NON | NON | ||
| 50 | AVA | NON |
Ylin
12,05VWAP
Alin
11,2VaihtoMäärä
0,6 52 890
VWAP
Ylin
12,05Alin
11,2VaihtoMäärä
0,6 52 890
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·13 t sitten · MuokattuI have created a strategic narrative/description of Curasight from an investor perspective (for full documentation, please refer to Master and Appendix in previously shared material) Market consensus seems to be: “Phase I, topline in 2026 - there is plenty of time.” In my assessment, that is a major misreading of reality. Curasight expects to have recruited all six patients in Phase I within the coming months, with topline in Q2 2026 – probably early in Q2. The process indicates low clinical and operational friction. At the same time, management states that they are engaged in strategic discussions towards the next value-creating step, which is after Phase I. My clear assessment is that dialogues with major Big Pharma players have already taken place in connection with JPM, under NDA and with sharing of non-public data, both for FPD and probably also 2nd patient. At this stage, Big Pharma does not look at endpoints, but whether the fundamental prerequisites are in place: ✔ Target validation in humans ✔ Retention for dosimetry ✔ No early safety or toxicity warnings ✔ A program without friction ✔ A disciplined and data-driven management 👉The only open question is variance and reproducibility (patient 3–6). Bottom line: The next value-creating step for Curasight is not necessarily topline results. In theranostics, history has repeatedly shown that value creation can just as well come in the form of a strategic partnership agreement, an optioned structure - or simply by a Big Pharma decision already having been made, long before the market becomes aware of it. The market waits for topline --> Big Pharma waits for patterns. Link to the narrative/description: https://drive.google.com/file/d/1MEqltPss2Y5kjbcg7Vyv9Ifv86R0ig9T/view?usp=drive_link ------------------------------------------------------------------------------------ Disclaimer: This is not a buy recommendation. The material has been prepared solely for personal use and reflection. I myself own shares in Curasight.
·1 päivä sittenOut of pure boredom (and since it's now the weekend and we might as well speculate a little); Curium posted this little teaser video on YouTube two days ago...and doesn't it just implicitly scream 'Curasight' ;)?? https://youtu.be/Dc39iOsT-fw?si=tZHMMcKzWI2dNdEL Curasight's 'motto', "what you see is what you treat" is almost paraphrased 1-1 in the video ("Treat what you see, see what you treat" ). How big is the possibility that Curium and Curasight will expand the partnership agreement...?
·16 t sittenTwo questions: Isn't Currium on the stock exchange? And what is the difference between Currium and Curesight, if Currium does the same, Trace and Treat?
·3 t sitten · MuokattuGemini answers, as it is faster at writing everything down than I am 😅 No, Curium Pharma is not listed on the stock exchange. The company is privately owned. It was recapitalized in late 2025 (November) in a huge deal valued at approx. 7 billion USD. The private equity fund CapVest Partners is the main shareholder through a new fund structure together with other institutional investors. Even though you cannot buy Curium shares directly, their activities are of great importance to Curasight, as they are strategic partners. 2. The difference between Curium and Curasight Although both work with "Trace and Treat" (theranostics), they play vastly different roles in the value chain: 1) Characteristic Curasight (Biotech developer) 2) Curium (Global Market Leader) 1) Status Listed (Ticker: CURAS). 2) Privately owned (owned by private equity funds). 1) Role Inventor of the uPAR platform. Producer and distributor ("Big Pharma" within nuclear medicine). Technology Owns the rights to uTRACE® and uTREAT®. 2) Supplies radioactive isotopes (e.g. Lutetium-177) and has the production apparatus. 1) Collaboration Develops the technology until approval. 2) Has a license for uTrace in prostate cancer and is responsible for global sales/production In short: Curasight are the innovative minds behind the uPAR technology (the "recipe" itself). Curium is the global giant with "the kitchen" (the factories) and "the trucks" (the distribution network), which helps Curasight get their products out to millions of patients.
·2 päivää sittenAnyone expecting an update from Ulrich and co. here post JP Morgan? There are a couple of interesting things currently, _ dare one address the elephant in the room now or should it remain in the room for months without further info (that the company itself has announced that post uTreat prlm, data they had what was needed for Big Pharma to assess the case). _ dare one trust that a status update will come soon - which will clarify the process from here and 6-18 months ahead. That was something that worked incredibly well last year. The case needs the timeline to be clarified before too long, as it previously just stated "uTrace preliminary efficacy data and topline results ph2 (with Curium) in H1 2026. " Silence is probably not entirely bad for once, isolated, as at this stage it might be difficult to communicate certain things before they actually happen. Or what - I'm actually a bit unsure if one is allowed/could consider addressing any interest that has arisen for the case post. JP Morgan. Because that probably borders on market manipulation... Just like one cannot announce when money will come from Curium, even if one might have a presumption... I think? There are extremely many interesting things lurking around the corner, but they have to remain hidden.- ·3 päivää sittenExciting now. Whether one has more to deploy here and now - or if one must prepare for a spring that might resemble autumn. Slight quiet, pipeline intact but no new ones are really picking it up. How low can it trickle. Wildly many possible triggers, with emphasis on possible. The market awaits. Exciting if it stays in 11,5-12,5 or if it has to go further down - in the autumn it didn't handle it super well and one entered a 2 month stretch that meant almost -35% down. Without the case itself having changed - and the company genuinely does what they say they do. Technically a bit sad to see that a similar fall would mean hitting this small dilution that looms - one must hope it never comes to that.·2 päivää sittenI have added a bit to today's fall today; latest news (and possibility for new partner agreement within x number of weeks/months) is not priced in imo... That the price has risen considerably in the last 6mdr is in my opinion irrelevant; summer's capital increase forced it down.·2 päivää sittenNo; they have just completed a directed issue in December, as well as received money via loans; they are currently very strong and have announced that they And with potential milestone payments and a new partner agreement within the next months, more will be added to the coffers. See, among other things, here: "The Board of Directors assesses that the net proceeds from the Financing will be sufficient to fund the Company's operations to the end of 2026." https://www.inderes.dk/releases/curasight-as-has-successfully-completed-a-directed-issue-of-shares-of-approximately-dkk-164-million-and-has-entered-into-a-new-loan-facility
- ·3 päivää sittenNew Q&A with Ulrich K: https://biostock.se/2026/01/curasight-rapporterer-uppmuntrande-preliminara-data-fran-utreat-fas-i-studie/?fbclid=Iwb21leAPVhR5jbGNrA9WEvWV4dG4DYWVtAjExAHNydGMGYXBwX2lkDDM1MDY4NTUzMTcyOAABHkni-JNxCdWBBmbeKyBoULP1jPDSsEQAaEkZf7e8chH8VAXDuG1qVrjWduXh_aem_uzSX_Xt1O6DcX3pkdfnuHA Excerpt from the article: "We are very focused on progressing our clinical efforts for uTREAT and completing the Phase 1 glioblastoma trial. In parallel, we are strengthening our regulatory preparedness, continuing to expand the clinical and translational data package, and engaging in strategic discussions to ensure we are well-positioned for the next value-inflection points following data read-out." 🙌🙌👏
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
48 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·13 t sitten · MuokattuI have created a strategic narrative/description of Curasight from an investor perspective (for full documentation, please refer to Master and Appendix in previously shared material) Market consensus seems to be: “Phase I, topline in 2026 - there is plenty of time.” In my assessment, that is a major misreading of reality. Curasight expects to have recruited all six patients in Phase I within the coming months, with topline in Q2 2026 – probably early in Q2. The process indicates low clinical and operational friction. At the same time, management states that they are engaged in strategic discussions towards the next value-creating step, which is after Phase I. My clear assessment is that dialogues with major Big Pharma players have already taken place in connection with JPM, under NDA and with sharing of non-public data, both for FPD and probably also 2nd patient. At this stage, Big Pharma does not look at endpoints, but whether the fundamental prerequisites are in place: ✔ Target validation in humans ✔ Retention for dosimetry ✔ No early safety or toxicity warnings ✔ A program without friction ✔ A disciplined and data-driven management 👉The only open question is variance and reproducibility (patient 3–6). Bottom line: The next value-creating step for Curasight is not necessarily topline results. In theranostics, history has repeatedly shown that value creation can just as well come in the form of a strategic partnership agreement, an optioned structure - or simply by a Big Pharma decision already having been made, long before the market becomes aware of it. The market waits for topline --> Big Pharma waits for patterns. Link to the narrative/description: https://drive.google.com/file/d/1MEqltPss2Y5kjbcg7Vyv9Ifv86R0ig9T/view?usp=drive_link ------------------------------------------------------------------------------------ Disclaimer: This is not a buy recommendation. The material has been prepared solely for personal use and reflection. I myself own shares in Curasight.
- ·1 päivä sittenOut of pure boredom (and since it's now the weekend and we might as well speculate a little); Curium posted this little teaser video on YouTube two days ago...and doesn't it just implicitly scream 'Curasight' ;)?? https://youtu.be/Dc39iOsT-fw?si=tZHMMcKzWI2dNdEL Curasight's 'motto', "what you see is what you treat" is almost paraphrased 1-1 in the video ("Treat what you see, see what you treat" ). How big is the possibility that Curium and Curasight will expand the partnership agreement...?·16 t sittenTwo questions: Isn't Currium on the stock exchange? And what is the difference between Currium and Curesight, if Currium does the same, Trace and Treat?·3 t sitten · MuokattuGemini answers, as it is faster at writing everything down than I am 😅 No, Curium Pharma is not listed on the stock exchange. The company is privately owned. It was recapitalized in late 2025 (November) in a huge deal valued at approx. 7 billion USD. The private equity fund CapVest Partners is the main shareholder through a new fund structure together with other institutional investors. Even though you cannot buy Curium shares directly, their activities are of great importance to Curasight, as they are strategic partners. 2. The difference between Curium and Curasight Although both work with "Trace and Treat" (theranostics), they play vastly different roles in the value chain: 1) Characteristic Curasight (Biotech developer) 2) Curium (Global Market Leader) 1) Status Listed (Ticker: CURAS). 2) Privately owned (owned by private equity funds). 1) Role Inventor of the uPAR platform. Producer and distributor ("Big Pharma" within nuclear medicine). Technology Owns the rights to uTRACE® and uTREAT®. 2) Supplies radioactive isotopes (e.g. Lutetium-177) and has the production apparatus. 1) Collaboration Develops the technology until approval. 2) Has a license for uTrace in prostate cancer and is responsible for global sales/production In short: Curasight are the innovative minds behind the uPAR technology (the "recipe" itself). Curium is the global giant with "the kitchen" (the factories) and "the trucks" (the distribution network), which helps Curasight get their products out to millions of patients.
- ·2 päivää sittenAnyone expecting an update from Ulrich and co. here post JP Morgan? There are a couple of interesting things currently, _ dare one address the elephant in the room now or should it remain in the room for months without further info (that the company itself has announced that post uTreat prlm, data they had what was needed for Big Pharma to assess the case). _ dare one trust that a status update will come soon - which will clarify the process from here and 6-18 months ahead. That was something that worked incredibly well last year. The case needs the timeline to be clarified before too long, as it previously just stated "uTrace preliminary efficacy data and topline results ph2 (with Curium) in H1 2026. " Silence is probably not entirely bad for once, isolated, as at this stage it might be difficult to communicate certain things before they actually happen. Or what - I'm actually a bit unsure if one is allowed/could consider addressing any interest that has arisen for the case post. JP Morgan. Because that probably borders on market manipulation... Just like one cannot announce when money will come from Curium, even if one might have a presumption... I think? There are extremely many interesting things lurking around the corner, but they have to remain hidden.
- ·3 päivää sittenExciting now. Whether one has more to deploy here and now - or if one must prepare for a spring that might resemble autumn. Slight quiet, pipeline intact but no new ones are really picking it up. How low can it trickle. Wildly many possible triggers, with emphasis on possible. The market awaits. Exciting if it stays in 11,5-12,5 or if it has to go further down - in the autumn it didn't handle it super well and one entered a 2 month stretch that meant almost -35% down. Without the case itself having changed - and the company genuinely does what they say they do. Technically a bit sad to see that a similar fall would mean hitting this small dilution that looms - one must hope it never comes to that.·2 päivää sittenI have added a bit to today's fall today; latest news (and possibility for new partner agreement within x number of weeks/months) is not priced in imo... That the price has risen considerably in the last 6mdr is in my opinion irrelevant; summer's capital increase forced it down.·2 päivää sittenNo; they have just completed a directed issue in December, as well as received money via loans; they are currently very strong and have announced that they And with potential milestone payments and a new partner agreement within the next months, more will be added to the coffers. See, among other things, here: "The Board of Directors assesses that the net proceeds from the Financing will be sufficient to fund the Company's operations to the end of 2026." https://www.inderes.dk/releases/curasight-as-has-successfully-completed-a-directed-issue-of-shares-of-approximately-dkk-164-million-and-has-entered-into-a-new-loan-facility
- ·3 päivää sittenNew Q&A with Ulrich K: https://biostock.se/2026/01/curasight-rapporterer-uppmuntrande-preliminara-data-fran-utreat-fas-i-studie/?fbclid=Iwb21leAPVhR5jbGNrA9WEvWV4dG4DYWVtAjExAHNydGMGYXBwX2lkDDM1MDY4NTUzMTcyOAABHkni-JNxCdWBBmbeKyBoULP1jPDSsEQAaEkZf7e8chH8VAXDuG1qVrjWduXh_aem_uzSX_Xt1O6DcX3pkdfnuHA Excerpt from the article: "We are very focused on progressing our clinical efforts for uTREAT and completing the Phase 1 glioblastoma trial. In parallel, we are strengthening our regulatory preparedness, continuing to expand the clinical and translational data package, and engaging in strategic discussions to ensure we are well-positioned for the next value-inflection points following data read-out." 🙌🙌👏
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
925
Myynti
Määrä
300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 300 | AVA | NON | ||
| 57 | NON | AVA | ||
| 20 | NON | NON | ||
| 500 | NON | NON | ||
| 50 | AVA | NON |
Ylin
12,05VWAP
Alin
11,2VaihtoMäärä
0,6 52 890
VWAP
Ylin
12,05Alin
11,2VaihtoMäärä
0,6 52 890
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
2025 Q3 -tulosraportti
48 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·13 t sitten · MuokattuI have created a strategic narrative/description of Curasight from an investor perspective (for full documentation, please refer to Master and Appendix in previously shared material) Market consensus seems to be: “Phase I, topline in 2026 - there is plenty of time.” In my assessment, that is a major misreading of reality. Curasight expects to have recruited all six patients in Phase I within the coming months, with topline in Q2 2026 – probably early in Q2. The process indicates low clinical and operational friction. At the same time, management states that they are engaged in strategic discussions towards the next value-creating step, which is after Phase I. My clear assessment is that dialogues with major Big Pharma players have already taken place in connection with JPM, under NDA and with sharing of non-public data, both for FPD and probably also 2nd patient. At this stage, Big Pharma does not look at endpoints, but whether the fundamental prerequisites are in place: ✔ Target validation in humans ✔ Retention for dosimetry ✔ No early safety or toxicity warnings ✔ A program without friction ✔ A disciplined and data-driven management 👉The only open question is variance and reproducibility (patient 3–6). Bottom line: The next value-creating step for Curasight is not necessarily topline results. In theranostics, history has repeatedly shown that value creation can just as well come in the form of a strategic partnership agreement, an optioned structure - or simply by a Big Pharma decision already having been made, long before the market becomes aware of it. The market waits for topline --> Big Pharma waits for patterns. Link to the narrative/description: https://drive.google.com/file/d/1MEqltPss2Y5kjbcg7Vyv9Ifv86R0ig9T/view?usp=drive_link ------------------------------------------------------------------------------------ Disclaimer: This is not a buy recommendation. The material has been prepared solely for personal use and reflection. I myself own shares in Curasight.
- ·1 päivä sittenOut of pure boredom (and since it's now the weekend and we might as well speculate a little); Curium posted this little teaser video on YouTube two days ago...and doesn't it just implicitly scream 'Curasight' ;)?? https://youtu.be/Dc39iOsT-fw?si=tZHMMcKzWI2dNdEL Curasight's 'motto', "what you see is what you treat" is almost paraphrased 1-1 in the video ("Treat what you see, see what you treat" ). How big is the possibility that Curium and Curasight will expand the partnership agreement...?·16 t sittenTwo questions: Isn't Currium on the stock exchange? And what is the difference between Currium and Curesight, if Currium does the same, Trace and Treat?·3 t sitten · MuokattuGemini answers, as it is faster at writing everything down than I am 😅 No, Curium Pharma is not listed on the stock exchange. The company is privately owned. It was recapitalized in late 2025 (November) in a huge deal valued at approx. 7 billion USD. The private equity fund CapVest Partners is the main shareholder through a new fund structure together with other institutional investors. Even though you cannot buy Curium shares directly, their activities are of great importance to Curasight, as they are strategic partners. 2. The difference between Curium and Curasight Although both work with "Trace and Treat" (theranostics), they play vastly different roles in the value chain: 1) Characteristic Curasight (Biotech developer) 2) Curium (Global Market Leader) 1) Status Listed (Ticker: CURAS). 2) Privately owned (owned by private equity funds). 1) Role Inventor of the uPAR platform. Producer and distributor ("Big Pharma" within nuclear medicine). Technology Owns the rights to uTRACE® and uTREAT®. 2) Supplies radioactive isotopes (e.g. Lutetium-177) and has the production apparatus. 1) Collaboration Develops the technology until approval. 2) Has a license for uTrace in prostate cancer and is responsible for global sales/production In short: Curasight are the innovative minds behind the uPAR technology (the "recipe" itself). Curium is the global giant with "the kitchen" (the factories) and "the trucks" (the distribution network), which helps Curasight get their products out to millions of patients.
- ·2 päivää sittenAnyone expecting an update from Ulrich and co. here post JP Morgan? There are a couple of interesting things currently, _ dare one address the elephant in the room now or should it remain in the room for months without further info (that the company itself has announced that post uTreat prlm, data they had what was needed for Big Pharma to assess the case). _ dare one trust that a status update will come soon - which will clarify the process from here and 6-18 months ahead. That was something that worked incredibly well last year. The case needs the timeline to be clarified before too long, as it previously just stated "uTrace preliminary efficacy data and topline results ph2 (with Curium) in H1 2026. " Silence is probably not entirely bad for once, isolated, as at this stage it might be difficult to communicate certain things before they actually happen. Or what - I'm actually a bit unsure if one is allowed/could consider addressing any interest that has arisen for the case post. JP Morgan. Because that probably borders on market manipulation... Just like one cannot announce when money will come from Curium, even if one might have a presumption... I think? There are extremely many interesting things lurking around the corner, but they have to remain hidden.
- ·3 päivää sittenExciting now. Whether one has more to deploy here and now - or if one must prepare for a spring that might resemble autumn. Slight quiet, pipeline intact but no new ones are really picking it up. How low can it trickle. Wildly many possible triggers, with emphasis on possible. The market awaits. Exciting if it stays in 11,5-12,5 or if it has to go further down - in the autumn it didn't handle it super well and one entered a 2 month stretch that meant almost -35% down. Without the case itself having changed - and the company genuinely does what they say they do. Technically a bit sad to see that a similar fall would mean hitting this small dilution that looms - one must hope it never comes to that.·2 päivää sittenI have added a bit to today's fall today; latest news (and possibility for new partner agreement within x number of weeks/months) is not priced in imo... That the price has risen considerably in the last 6mdr is in my opinion irrelevant; summer's capital increase forced it down.·2 päivää sittenNo; they have just completed a directed issue in December, as well as received money via loans; they are currently very strong and have announced that they And with potential milestone payments and a new partner agreement within the next months, more will be added to the coffers. See, among other things, here: "The Board of Directors assesses that the net proceeds from the Financing will be sufficient to fund the Company's operations to the end of 2026." https://www.inderes.dk/releases/curasight-as-has-successfully-completed-a-directed-issue-of-shares-of-approximately-dkk-164-million-and-has-entered-into-a-new-loan-facility
- ·3 päivää sittenNew Q&A with Ulrich K: https://biostock.se/2026/01/curasight-rapporterer-uppmuntrande-preliminara-data-fran-utreat-fas-i-studie/?fbclid=Iwb21leAPVhR5jbGNrA9WEvWV4dG4DYWVtAjExAHNydGMGYXBwX2lkDDM1MDY4NTUzMTcyOAABHkni-JNxCdWBBmbeKyBoULP1jPDSsEQAaEkZf7e8chH8VAXDuG1qVrjWduXh_aem_uzSX_Xt1O6DcX3pkdfnuHA Excerpt from the article: "We are very focused on progressing our clinical efforts for uTREAT and completing the Phase 1 glioblastoma trial. In parallel, we are strengthening our regulatory preparedness, continuing to expand the clinical and translational data package, and engaging in strategic discussions to ensure we are well-positioned for the next value-inflection points following data read-out." 🙌🙌👏
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
925
Myynti
Määrä
300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 300 | AVA | NON | ||
| 57 | NON | AVA | ||
| 20 | NON | NON | ||
| 500 | NON | NON | ||
| 50 | AVA | NON |
Ylin
12,05VWAP
Alin
11,2VaihtoMäärä
0,6 52 890
VWAP
Ylin
12,05Alin
11,2VaihtoMäärä
0,6 52 890
Välittäjätilasto
Dataa ei löytynyt